Table 2 Canfosfamide and pegylated liposomal doxorubicin treatment administration and adjunctive care (N = 39)
Dosing (Total # of Cycles = 245) | Canfosfamide | PLD |
Median # Cycles/Patient (range) | 4.0 (1-18.0) | |
Median Cumulative Dose, mg/m2 (range) | 3840 (960.0-13978) | 200.3 (50.0-726.4) |
Dose Reductions | 28 | 31 |
Dose Interruptions | 14 | 6 |
Adjunctive Treatment | # Cycles | % Cycles |
Granulocyte Growth Factor Support | 79 | 32.2 |
Erythropoietin Support | 49 | 20.0 |
RBC Transfusions | 18 | 7.3 |
Platelet Transfusions | 1 | 0.4 |